Doximity (NASDAQ:DOCS) Research Coverage Started at Stephens

Stephens assumed coverage on shares of Doximity (NASDAQ:DOCSFree Report) in a research report released on Friday morning, Marketbeat Ratings reports. The brokerage issued an equal weight rating and a $55.00 target price on the stock.

A number of other equities analysts also recently commented on the company. Mizuho initiated coverage on Doximity in a report on Wednesday, December 4th. They issued a “neutral” rating and a $55.00 price objective on the stock. Canaccord Genuity Group lowered shares of Doximity from a “buy” rating to a “hold” rating and increased their price target for the stock from $40.00 to $60.00 in a research note on Wednesday, November 13th. Morgan Stanley raised shares of Doximity from an “underweight” rating to an “equal weight” rating and lifted their price objective for the company from $33.00 to $53.00 in a research note on Thursday, November 14th. The Goldman Sachs Group started coverage on shares of Doximity in a research report on Friday, November 15th. They set a “neutral” rating and a $58.00 target price on the stock. Finally, Barclays boosted their price target on Doximity from $52.00 to $75.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Thirteen investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $52.59.

Check Out Our Latest Report on Doximity

Doximity Price Performance

Shares of DOCS stock opened at $57.83 on Friday. Doximity has a fifty-two week low of $22.96 and a fifty-two week high of $61.75. The stock’s 50-day moving average is $49.11 and its two-hundred day moving average is $38.86. The firm has a market cap of $10.80 billion, a P/E ratio of 66.47, a PEG ratio of 4.16 and a beta of 1.40.

Hedge Funds Weigh In On Doximity

Large investors have recently bought and sold shares of the stock. MetLife Investment Management LLC increased its holdings in shares of Doximity by 0.6% during the 3rd quarter. MetLife Investment Management LLC now owns 65,064 shares of the company’s stock worth $2,835,000 after purchasing an additional 363 shares during the period. First Horizon Advisors Inc. grew its position in Doximity by 22.5% during the third quarter. First Horizon Advisors Inc. now owns 2,094 shares of the company’s stock worth $91,000 after buying an additional 384 shares in the last quarter. GAMMA Investing LLC increased its stake in Doximity by 40.1% during the third quarter. GAMMA Investing LLC now owns 1,439 shares of the company’s stock valued at $63,000 after acquiring an additional 412 shares during the period. Van ECK Associates Corp raised its holdings in Doximity by 19.7% in the 2nd quarter. Van ECK Associates Corp now owns 2,590 shares of the company’s stock valued at $72,000 after acquiring an additional 427 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. lifted its position in shares of Doximity by 3.2% in the 2nd quarter. Cornercap Investment Counsel Inc. now owns 17,143 shares of the company’s stock worth $479,000 after acquiring an additional 537 shares during the period. 87.19% of the stock is currently owned by institutional investors and hedge funds.

Doximity Company Profile

(Get Free Report)

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.

Further Reading

Analyst Recommendations for Doximity (NASDAQ:DOCS)

Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.